Log in

Relevant bibliographies by topics / 004.056.5; 57.087.2(043.2) / Journal articles

To see the other types of publications on this topic, follow the link: 004.056.5; 57.087.2(043.2).

Journal articles on the topic '004.056.5; 57.087.2(043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '004.056.5; 57.087.2(043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tsimberidou, A. M., C. Tam, W. Wierda, S. O' Brien, S. Lerner, and M. J. Keating. "Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7034.

Full text

Abstract:

7034 Introduction: High β2M levels are a risk factor in CLL. PCR therapy has been reported to be better tolerated than FCR in older or with decrease renal function pts (Shanafelt, Blood 108:15a). We assessed the association between age, CrCl, PS, β2M and outcomes in pts treated with FCR. Methods: From 7/99 to 1/04, 300 pts received rituximab 375 mg/m2 D1; fludarabine 25 mg/m2/d D2–3; and cyclophosphamide 250 mg/m2/d D2–3. Serum β2M levels were measured by radioimmunoassay. CrCl was calculated (Cockcroft-Gault equation). Results: The median age was 57 yrs (≥70, 14%). Age ≥70 was associated with

APA, Harvard, Vancouver, ISO, and other styles

2

Baron, Frederic, Myriam Labopin, Mohamad Mohty, et al. "Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT." Blood 114, no. 22 (2009): 3313. http://dx.doi.org/10.1182/blood.v114.22.3313.3313.

Full text

Abstract:

Abstract Abstract 3313 Poster Board III-201 RIC allo-SCT has been increasingly used as treatment for AML patients (pts) ineligible for myeloablative allo-SCT. Previous studies have observed a lower risk of relapse in pts who experienced chronic GVHD after RIC allo-SCT versus in those who did not. The objective of the current study was to further investigate the association between chronic GVHD and relapse in a large cohort of pts given RIC allo-SCT as treatment for AML. Data from 1188 AML pts in first or second CR transplanted between 2000 and 2008 following a RIC regimen at EBMT affiliated ce

APA, Harvard, Vancouver, ISO, and other styles

3

Willasch, Andre Manfred, Christina Peters, Petr Sedlacek, et al. "Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study." Blood 130, Suppl_1 (2017): 911. http://dx.doi.org/10.1182/blood.v130.suppl_1.911.911.

Full text

Abstract:

Abstract Introduction: Most pediatric patients (pts) with ALL receive total body irradiation (TBI) for myeloablative conditioning of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is unproven whether TBI can be replaced by chemotherapy (CHT). Methods: To compare the outcomes of TBI- versus (vs.) CHT-based conditioning, we performed a retrospective EBMT-registry based study. Children between 2 and 18 years of age (y.) after myeloablative conditioning for first allo-HSCT of bone marrow (BM) or peripheral blood SC (PBSC) from matched sibling (MSD) or unrelated donors (UD) in f

APA, Harvard, Vancouver, ISO, and other styles

4

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Full text

Abstract:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

APA, Harvard, Vancouver, ISO, and other styles

5

Della Porta, Matteo G., Emilio Paolo Alessandrino, Andrea Bacigalupo, et al. "The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making." Blood 122, no. 21 (2013): 2765. http://dx.doi.org/10.1182/blood.v122.21.2765.2765.

Full text

Abstract:

Abstract Background The only curative treatment for patients with myelodysplastic syndrome (MDS) is allogeneic stem cell transplantation (allo-SCT). Decision to transplant is currently based on the International Prognostic Scoring System (IPSS), which has limitations. Recently, a revised IPSS (IPSS-R) has been developed (Blood. 2012;120:2454-2465). Aim To identify predictive factors for transplantation outcome, we studied 519 patients with MDS or acute myeloid leukemia (AML) evolving from MDS who received allo-SCT and were reported to the GITMO registry between 2000 and 2010. Results 1 Posttra

APA, Harvard, Vancouver, ISO, and other styles

6

Wang, Yu, and Xiao Jun Huang. "Donor Selection For Haploidentical Hematopoietic Stem Cell Transplantation: Who Is The Better – Donor-Recipient Risk Factor Analysis." Blood 122, no. 21 (2013): 705. http://dx.doi.org/10.1182/blood.v122.21.705.705.

Full text

Abstract:

Abstract Background many aspects should be considered when selecting an ideal donor. The progress made in haploidentical HSCT in recent years offers almost unlimited donor and availabilities of more than one donor at many occasions. To date, there have been no studies to answer the question of apart from HLA disparity, whether one donor should be preferred over another among various haploidentical donors available. The goal of the current study was to attempt to answer the question by analyzing the data on haploidentical HSCT without in-vitro T cell depletion modality. Methods Consecutive pati

APA, Harvard, Vancouver, ISO, and other styles

7

Kuendgen, Andrea, Michael Lauseker, Alan F. List, et al. "Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study." Blood 118, no. 21 (2011): 119. http://dx.doi.org/10.1182/blood.v118.21.119.119.

Full text

Abstract:

Abstract Abstract 119 Background: Lenalidomide (LEN) treatment resulted in RBC transfusion independence for ≥ 8 wks in 51–67% of patients (pts) and cytogenetic response in 25–73% of pts with lower-risk MDS and del5q in 2 large multicenter trials (MDS-003 and -004) (List A et al. NEJM 2006;355:1456–65; Fenaux P et al. Blood 2011; doi:10.1182/blood-2011-01-330126). However, these studies were either single-arm or allowed early crossover to LEN, thus data on the influence of LEN on AML progression and overall survival (OS) is lacking. Aims: To assess the risk of AML progression and death in LEN-t

APA, Harvard, Vancouver, ISO, and other styles

8

Nakayama, Y., R. Nakashima, T. Handa, et al. "POS1051 LUNG CLUSTERING ANALYSIS-BASED PHENOTYPES OF RHEUMATOID ARTHRITIS USING ARTIFICIAL INTELLIGENCE-BASED TECHNOLOGY FOR CHEST COMPUTED TOMOGRAPHY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 843.1–844. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2178.

Full text

Abstract:

BackgroundLung involvement is a prevalent extraarticular manifestation of rheumatoid arthritis (RA) that remains a significant clinical challenge. Few studies have comprehensively quantified lung abnormalities of RA patients using artificial intelligence-based (AI) technology.ObjectivesThe aim of this study was to quantify lung lesions in RA patients and classify them based on their lung parameters.MethodsAn AI-based quantitative computed tomography (CT) image analysis software (AIQCT) was applied to high-resolution CT scans of RA patients in a cross-sectional manner. AIQCT automatically class

APA, Harvard, Vancouver, ISO, and other styles

9

Lasa, Marta, Mario Nuvolone, Ioannis V. Kostopoulos, et al. "Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis." Blood 144, Supplement 1 (2024): 889. https://doi.org/10.1182/blood-2024-202995.

Full text

Abstract:

Background: Novel treatments targeting the plasma cell clone are increasing the rate of hematologic complete response (CR) and improving outcomes in AL amyloidosis. In multiple myeloma (MM), MRD negativity is considered the new CR and pivoted from a prognostic factor into a treatment endpoint and a surrogate for accelerated drug approval. By contrast, the role of MRD in AL amyloidosis remains uncertain and, accordingly, it is not routinely performed in clinical trials and practice. Aim: Investigate the clinical significance of MRD assessment in patients with AL amyloidosis. Methods: This multi

APA, Harvard, Vancouver, ISO, and other styles

10

Dörner, T., Y. Tanaka, M. Mosca, et al. "POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 639.1–639. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2375.

Full text

Abstract:

BackgroundBaricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE).ObjectivesTo assess the safety profile of BARI in patients with SLE.MethodsPatients with SLE receiving stable background therapy were randomised 1:1:1 to BARI 2-mg, 4-mg, or placebo (PBO) once daily in one 24-week, phase 2 (NCT02708095) and two 52-week, phase 3, PBO controlled studies (NCT03616912 and NCT03616964).ResultsA total of 1,849 patients were

APA, Harvard, Vancouver, ISO, and other styles

11

Zhu, Katie Y., Kevin W. Song, Joseph M. Connors, et al. "Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada." Blood 128, no. 22 (2016): 1113. http://dx.doi.org/10.1182/blood.v128.22.1113.1113.

Full text

Abstract:

Abstract Background: Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma associated with translocations involving the c-MYC oncogene on chromosome 8. The 1996 Magrath regimen, CODOX-M/IVAC, showed a promising 2-year (y) event free survival (EFS) of 92% in 41 BL patients (pts), with additional trials of a dose-modified regimen demonstrating 2y overall survival (OS) 70-82% and 2y progression-free survival (PFS) 64% (Mead et al). A recent trial demonstrated that with addition of R, 3y OS and EFS were 83% and 75% (Ribrag et al). We sought to determine survival outcomes of adult BL pt

APA, Harvard, Vancouver, ISO, and other styles

12

Moccia, Moccia A., Jane Donaldson, Mukesh Chhanabhai, et al. "The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era." Blood 114, no. 22 (2009): 1554. http://dx.doi.org/10.1182/blood.v114.22.1554.1554.

Full text

Abstract:

Abstract Abstract 1554 Poster Board I-577 Introduction The International Prognostic Factor Project Score (IPS) is the most widely utilized risk stratification index for Hodgkin lymphoma (HL) (Hasenclever, N Engl J Med, 1998). Based on patients treated before 1992, it incorporates 7 adverse risk features (male gender, age ≥45 y, stage IV, hemoglobin <105 g/L, WBC ≥15 × 109/L, lymphocyte count <0.6 × 109/L or <8% of differential, albumin <40 g/L) and predicts for a 5-year freedom-from progression (FFP) ranging from 42-84%.The IPS has not been validated in a more recently treated popu

APA, Harvard, Vancouver, ISO, and other styles

13

Murkin, John M., Sandra J. Adams, Elaine Pardy, McKenzie Quantz, F. Neil McKenzie, and Linrui Guo. "Monitoring Brain Oxygen Saturation During Coronary Bypass Surgery Improves Outcomes in Diabetic Patients: A Post Hoc Analysis." Heart Surgery Forum 14, no. 1 (2011): 1. http://dx.doi.org/10.1532/hsf98.20101065.

Full text

Abstract:

Background: Having previously demonstrated in a prospective study of 200 coronary artery bypass (CAB) patients that by using the brain as an index organ, interventions to improve cerebral oxygenation would have systemic outcome benefits, we undertook a post hoc analysis of the diabetic subset (n = 57) of the overall study group to determine whether the outcomes of these patients were similarly improved.Methods: Case-report forms for the 200 CAB patients study patients with a preoperative diagnosis of diabetes mellitus were stratified to intraoperative cerebral regional oxygen saturation (rSO2)

APA, Harvard, Vancouver, ISO, and other styles

14

Zimmer, A., A. Klein та G. Horneff. "SAT0491 PSORIASIS ASSOCIATED WITH MONOCLONAL-ANTIBODY-TNF-Α INHIBITORS VS. FUSION PROTEIN ETANERCEPT IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS - ANALYSIS OF THE BIKER REGISTRY". Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1202.1–1202. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4883.

Full text

Abstract:

Background:Although efficacy of Tumor necrosis factor inhibitors (TNFi) for treatment of psoriasis is well established, patients may develop psoriasis for the first time while on TNFi as a paradoxical effect. Few data are available in patients with juvenile idiopathic arthritis (JIA).Objectives:To analyze the incidence of psoriasis in TNFi – treated JIA patients and to identify associated factors.Methods:Safety data from patients registered in the German Biologics registry (BIKeR) were analyzed. Cohorts of patients were grouped by treatment: any or multiple TNFi, single TNFi, biologics other t

APA, Harvard, Vancouver, ISO, and other styles

15

Mandel, Philipp, Benedikt Hoeh, Carolin Siech, et al. "Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy." Journal of Clinical Oncology 43, no. 5_suppl (2025): 79. https://doi.org/10.1200/jco.2025.43.5_suppl.79.

Full text

Abstract:

79 Background: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxane-based chemotherapy. However, its effect in taxane-naïve patients is under current investigation. Methods: We relied on the FRAMCAP database to elaborate Lu-PSMA therapy outcomes of progression-free (PFS) and overall (OS) in taxane-naïve mCRPC patients after previous ARPI treatment. Comparison was made against current standard of care with ARPI or docetaxel. Results: O

APA, Harvard, Vancouver, ISO, and other styles

16

Gotelli, E., P. F. Bica, T. Aloe’, et al. "AB0679 NAILFOLD VIDEOCAPILLAROSCOPY RESULTS IN COVID-19 PATIENTS RECOVERED FROM DIFFERENT DISEASE SEVERITY." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1372.2–1373. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2526.

Full text

Abstract:

Background:COVID-19 is a multifaceted condition with a wide range of clinical manifestations, including microvascular/endothelial dysfunction, that starts in the early phase of the disease and may become dramatically harmful in the late stage, causing a massive pro-thrombotic state. Nailfold videocapillaroscopy (NVC) is the most used tool to identify microvascular status in a large spectrum of diseases [1]. Recently, non-specific NVC abnormalities have been described in a cohort of COVID-19 patients (no controls used) [2].Objectives:To assess microvascular damage in recovered COVID-19 patients

APA, Harvard, Vancouver, ISO, and other styles

17

Winthrop, K., Y. Tanaka, T. Takeuchi, et al. "POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 354–55. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1631.

Full text

Abstract:

BackgroundThe preferential Janus kinase-1 inhibitor FIL significantly improved signs and symptoms of RA in Phase 2 and 3 trials.1–5 FIL is approved for treatment of moderate to severe active RA in Europe and Japan. Integrated safety analysis of FIL with patient data through 2019 was presented at the 2020 ACR virtual meeting.6ObjectivesTo report updated, as-treated data from the FIL integrated safety analysis with increased study drug exposure.MethodsData were integrated from 2 Phase 2 (NCT01668641, NCT01894516), 3 Phase 3 (NCT02889796, NCT02873936, NCT02886728), and 2 long-term extension (LTE)

APA, Harvard, Vancouver, ISO, and other styles

18

Martín Moro, Fernando, Ana Jiménez Ubieto, Marina Gomez Llobell, et al. "A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms." Blood 144, Supplement 1 (2024): 4478. https://doi.org/10.1182/blood-2024-212008.

Full text

Abstract:

Background: Plasmablastic neoplasms are rare and aggressive tumors that exhibit biological complexity and poor prognosis despite intensive approaches. Our aims were to evaluate the prognostic impact of clinical and biological variables in a series of plasmablastic neoplasms and to design a prognostic score. Besides, we analyzed the first-line therapeutic approach. Methods: Multicentric retrospective study within the Spanish Lymphoma Group (GELTAMO) including de novo plasmablastic neoplasms. Clinical, biological and therapeutic variables were analyzed, highlighting the evaluation of 17 markers

APA, Harvard, Vancouver, ISO, and other styles

19

Andersson, M., M. Zimmerman, E. Brogren, et al. "POS1363 CIRCULATING GALECTIN-1 LEVELS IN INDIVIDUALS WITH KNEE AND/OR HAND OSTEOARTHRITIS – A HALLOA STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1033–34. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2205.

Full text

Abstract:

BackgroundCirculating galectin-1 levels are associated with metabolic diseases including obesity, diabetes type II, and subclinical inflammation [1]. These medical conditions are often seen as comorbidities of osteoarthritis (OA) in the knees and hands.ObjectivesThe aim was to study longitudinal associations between circulating galectin-1 levels and radiographic knee OA (RKOA), radiographic hand OA (RHOA), and general OA (GOA, RKOA and RHOA).MethodsThis longitudinal study included 232 individuals from the Halland osteoarthritis cohort (HALLOA) (2) with knee radiographs at inclusion and at a tw

APA, Harvard, Vancouver, ISO, and other styles

20

Parker, Pablo M., Ryotaro Nakamura, Vinod Pullarket, et al. "Analysis of Predictive Power of Prednisone Dose at 3 Months of Treatment on CGVHD Prognosis." Blood 110, no. 11 (2007): 1975. http://dx.doi.org/10.1182/blood.v110.11.1975.1975.

Full text

Abstract:

Abstract Current CGVHD prognostic and staging systems are still undergoing development and have identified plt count; CGVHD types progressive(P), quiescent(Q), de novo(DN); KPS, and GI involvement as significant risk factors affecting outcome. A simple reproducible staging system such as used for AGVHD to apply in clinical trials is still lacking. We evaluated whether the PSE dose required to control CGVHD at 3 months from diagnosis would have a prognostic effect on survival and in and of itself serve as a criteria for secondary intervention or investigational therapy. We hypothesized that by

APA, Harvard, Vancouver, ISO, and other styles

21

Dallemagne, M., E. Ghys, D. De Troy, and I. Donnay. "259 DOES THE SENSITIVITY TO OXIDATIVE STRESS DEPEND ON THE SEX OF THE EMBRYO?" Reproduction, Fertility and Development 27, no. 1 (2015): 219. http://dx.doi.org/10.1071/rdv27n1ab259.

Full text

Abstract:

Male and female bovine embryos show several differences as early as the blastocyst stage. For example, differences are observed in metabolism, developmental kinetics, or gene expression that can lead to a shift in the sex ratio. Interestingly, the culture medium differentially affects male and female embryos. We previously showed that male Day 7 blastocysts present lower apoptotic rates than females (Ghys et al. 2013 Reprod. Fertil. Dev. 25, 194). The objective of the present study was to determine if such difference might be related to a differential sensitivity to oxidative stress, known to

APA, Harvard, Vancouver, ISO, and other styles

22

Aguirre, Luis E., Jan Philipp Bewersdorf, Yiwen Liu, et al. "Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics." Blood 144, Supplement 1 (2024): 4267. https://doi.org/10.1182/blood-2024-202744.

Full text

Abstract:

Background: Dismal survival outcomes are characteristic of pts with AML harboring very-high risk cytogenetics (vHRC), which can be attributed to aggressive disease biology and low and poorly durable response rates to conventional cytotoxic chemotherapy. Allogeneic hematopoietic stem cell transplant (alloSCT) is the preferred treatment strategy after major disease reduction with initial chemotherapy. However, it is unclear whether pts with AML-vHRC should be treated with intensive chemotherapy (IC) or hypomethylating agents plus venetoclax (HMA+ven) to achieve such responses. In this large mult

APA, Harvard, Vancouver, ISO, and other styles

23

Saini, Neeraj Y., Rima M. Saliba, Gabriela Rondon, et al. "Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types." Blood 132, Supplement 1 (2018): 3356. http://dx.doi.org/10.1182/blood-2018-99-117039.

Full text

Abstract:

Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (ASCT) remains a curative treatment for patients with advanced lymphomas. Haploidentical donors (HID) have recently extended transplantation for patients without HLA matched donors. Fludarabine (F) with melphalan (M) 140mg/m2 is the current standard of care conditioning regimen for ASCT. We hypothesized that progression-free survival (PFS) of patients with HID is comparable to that of HLA matched transplants, and that lower doses of melphalan (100mg/m2) are equally effective for these patients. Here, we analyzed outcomes

APA, Harvard, Vancouver, ISO, and other styles

24

Njenga, Daniel, Amos K. Mbugua, Collins Okoyo, and Sammy M. Njenga. "Intestinal Parasite Infections and Associated Risk Factors among Pre-School Aged Children in Kibera Informal Settlement, Nairobi, Kenya." East African Health Research Journal 6, no. 1 (2022): 86–97. http://dx.doi.org/10.24248/eahrj.v6i1.683.

Full text

Abstract:

Background: Infections with intestinal parasites are a major public health problem in children in developing countries like Kenya. School going children are considered at most risk and are included in school-based de-worming program. Less focus is given to pre-school children and information is scarce about intestinal parasitosis among this age group. In this study, we determined the prevalence and intensity of protozoa and helminth infections, and associated risk factors in an informal settlement. Methods: A community based cross-sectional study was conducted from October 2016 to January 2017

APA, Harvard, Vancouver, ISO, and other styles

25

Habib, Alma, Abdullah Mohammad Khan, Mehak M. Laharwal, et al. "A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment." Blood 144, Supplement 1 (2024): 7037. https://doi.org/10.1182/blood-2024-209283.

Full text

Abstract:

Introduction: In the pivotal clinical trial (MajesTEC-1), teclistamab-cqyv (Tec), a bispecific B-cell maturation antigen (BCMA)-directed T-cell engager, showed promising efficacy in terms of overall response rate and duration of response in heavily pretreated relapsed refractory multiple myeloma (RRMM); however, patients (pts) with an estimated glomerular filtration rate of &lt;40mL/min were excluded. The effect of Tec in treatment of RRMM in pts with baseline renal impairment (RI) is limited. Herein, we evaluated the impact of baseline RI on development of toxicities and outcomes in RRMM

APA, Harvard, Vancouver, ISO, and other styles

26

Thompson, Leslie A., Katherine A. Guthrie, Lihua Elizabeth Budde, et al. "The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma." Blood 118, no. 21 (2011): 2026. http://dx.doi.org/10.1182/blood.v118.21.2026.2026.

Full text

Abstract:

Abstract Abstract 2026 Background: High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is frequently employed to improve outcomes in patients with mantle cell lymphoma (MCL), yet results after transplant vary widely. We and others have shown that the Mantle Cell International Prognostic Index (MIPI) measured at diagnosis can predict overall survival (OS) after HDT and ASCT (Geisler, Blood 2010; Budde JCO 2011). Unfortunately, this approach is often limited at the time of transplant by the lack of available MIPI data from the time of diagnosis. Furthermore, the MIPI at diagn

APA, Harvard, Vancouver, ISO, and other styles

27

Mehta, Rohtesh S., Rima M. Saliba, Kai Cao, et al. "Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens." Blood 126, no. 23 (2015): 1190. http://dx.doi.org/10.1182/blood.v126.23.1190.1190.

Full text

Abstract:

Abstract Introduction: Double-unit cord blood (CB) transplantation (DCBT) after myeloablative conditioning, where one CB unit is expanded ex-vivo with mesenchymal precursor cells (MPC)-co-culture led to significantly improved neutrophil and platelet engraftment compared to historical controls.1 Our aim was to determine the efficacy of this technique after reduced-intensity conditioning (RIC) regimens. Methods: We evaluated consecutive adult patients with hematological malignancies who received RIC regimens followed by DCBT where one unit was infused unmanipulated and second unit was expanded e

APA, Harvard, Vancouver, ISO, and other styles

28

Van der Heijde, D., X. Baraliakos, M. Dougados, et al. "OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 12–13. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2441.

Full text

Abstract:

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in patients (pts) with active ankylosing spondylitis (AS).1,2ObjectivesTo assess efficacy and safety of BKZ vs placebo (PBO) in pts with active AS up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 2.MethodsBE MOBILE 2 (NCT03928743) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were aged ≥18 yrs, met modified New York criteria

APA, Harvard, Vancouver, ISO, and other styles

29

Mergenhagen, Kari A., Bethany A. Wattengel, Sara DiTursi, Jennifer Schroeck, and John A. Sellick. "1113. Outpatient Antimicrobial Stewardship: Targets for Urinary Tract Infections." Open Forum Infectious Diseases 6, Supplement_2 (2019): S396. http://dx.doi.org/10.1093/ofid/ofz360.977.

Full text

Abstract:

Abstract Background Urinary tract infections (UTIs) remain one of the most commonly diagnosed infectious diseases in the United States in both the inpatient and outpatient settings, accounting for 10.5 million outpatient visits in 2007. Of these visits, 5.4 million were seen in primary care offices. Outpatient antimicrobial stewardship programs are emerging and a focused approach to UTIs is needed to help guide new programs. Methods Data were collected by retrospective chart review of outpatient males at the VA Western New York Healthcare System using encounters from January 2005 to March 2018

APA, Harvard, Vancouver, ISO, and other styles

30

Kadia, Tapan, Farhad Ravandi, Naval Daver, et al. "Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia." Blood 126, no. 23 (2015): 4779. http://dx.doi.org/10.1182/blood.v126.23.4779.4779.

Full text

Abstract:

Abstract Background Immune-mediated destruction of hematopoietic stem (HSC) and progenitor cells, leading to their depletion, has been implicated as the pathophysiology behind bone marrow (BM) failure in aplastic anemia (AA). Immunosuppressive therapy (IST) using antithymocyte globulin (ATG) and cyclosporine has been successfully used in the treatment of cytopenias in patients (pts) with severe aplastic anemia (AA). Recently, the thrombomimetic eltrombopag (E-PAG) has been shown to have activity in refractory AA, presumably by increasing the numbers of BM HSCs. To simultaneously target both im

APA, Harvard, Vancouver, ISO, and other styles

31

Trotman, Judith, Katherine Rankin, Ibrahim Tohidi-Esfahani, et al. "Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)." Blood 144, Supplement 1 (2024): 4412. https://doi.org/10.1182/blood-2024-200334.

Full text

Abstract:

Introduction: BTKis are a mainstay of therapy for patients with WM, with most receiving continuous oral monotherapy for several years. While dosing is commonly interrupted, data on the impact of BTKi DIs on disease control remain limited. The phase 1/2 BGB-3111-AU-003 study (NCT02343120) evaluated zanubrutinib monotherapy in patients with B-cell malignancies. The subsequent phase 3 ASPEN study (NCT03053440) evaluated zanubrutinib vs ibrutinib in patients with MYD88 mutated WM and zanubrutinib in patients with MYD88 wild-type WM. At the end of each study, eligible patients (including those in t

APA, Harvard, Vancouver, ISO, and other styles

32

Markova, M., Juliet N. Barker, John E. Wagner, et al. "Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial." Blood 104, no. 11 (2004): 1825. http://dx.doi.org/10.1182/blood.v104.11.1825.1825.

Full text

Abstract:

Abstract Purine analogues have been combined with alkylator/irradiation as immunosuppressive and anti-tumor conditioning prior to allogeneic hematopoietic stem cell transplantation (HCT) though differing purine analogues have not been compared. We prospectively tested Fludarabine (F) 40 mg/m2/d x 5d vs. Cladribine (C) 10 mg/m2/d x 5d plus Busulfan (Bu) (2mg/kg q12h x 2d) and total body irradiation (T) 200cGy followed by cyclosporine and mycophenylate mofetil in 19 recipients of matched sibling peripheral blood stem cell and 13 unrelated donor (URD) marrow HCT. Patients in each randomly assigne

APA, Harvard, Vancouver, ISO, and other styles

33

Otrock, Zaher K., Bartlomiej P. Przychodzen, Holleh D. Husseinzadeh, et al. "Molecular Predictors Of Response To Lenalidomide In Myeloid Malignancies." Blood 122, no. 21 (2013): 2807. http://dx.doi.org/10.1182/blood.v122.21.2807.2807.

Full text

Abstract:

Abstract Lenalidomide (LEN) is effective in alleviating anemia in patients with MDS. Patients with del5q show particularly good responsiveness to LEN, but this drug has a significant activity in MDS patients without del5q and those with MDS/MPN and MPN. Currently, apart from del5q no routine molecular biomarkers have been identified to better predict response to LEN. Here, based on ability to perform a broad, unbiased mutational screen using generation sequencing (NGS) we hypothesized that somatic mutational patterns may help identify patients with myeloid malignancies who would benefit from L

APA, Harvard, Vancouver, ISO, and other styles

34

Taskina, E., E. Strebkova, L. Alekseeva, et al. "POS0130 ASSOCIATION BETWEEN HYPERTENSION AND OSTEOARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 276.2–277. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3859.

Full text

Abstract:

Background:Objectives:To evaluate the relationship between arterial hypertension (AH) and the course of knee osteoarthritis (OA).Methods:The prospective study included 109 women aged 38-75 y.o., of I-III Kellgren J. - Lawrence J. stage of knee OA (ACR), who signed an informed consent. The average age was 59.3 ± 8.7 y.o. (from 38 to 74), the average duration of the OA was 7 (4-12) years. The average values of the body mass index (BMI) corresponded to obesity (30.9 ± 5.4 kg / m2), waist circumference (WC) – 94.4 ± 11.7 cm. An individual card was filled in for each patient, including anthropometr

APA, Harvard, Vancouver, ISO, and other styles

35

Hunault-Berger, Mathilde, Yves Gruel, Jean-Luc Harousseau, et al. "Evolution of Antithrombin (AT) and Fibrinogen (Fg) Levels during Induction Chemotherapy with L-Asparaginase (Asp) in Adult Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). Clinical Outcomes and Use of Coagulation Supportive Treatments: The CAPELAL Study." Blood 104, no. 11 (2004): 4486. http://dx.doi.org/10.1182/blood.v104.11.4486.4486.

Full text

Abstract:

Abstract The incidence of AT and Fg deficiency and of thrombotic and bleeding events after Asp has been well evaluated in children with ALL, but little is known in adults. In this study, the incidence of these events and the use of coagulation supportive treatments was evaluated in 214 adult patients with ALL (n= 191) or LBL (n=23) included in the GOELAL02 trial (Blood 2004, in press). The induction therapy included steroids (40 mg/m2/d d1-21), vincristine (2 mg d1, 8, 15, 22), idarubicine (5 mg/m2 d1, 8,15, 22) and Asp (7500 UI/m2 d10, 13, 16, 19, 22, 25) delivered through a central venous ac

APA, Harvard, Vancouver, ISO, and other styles

36

Thiele, K., K. Albrecht, A. Zink, et al. "POS0002 IS THE RHEUMATOID ARTHRITIS IMPACT OF DISEASE SCORE (RAID) AN INFORMATIVE INSTRUMENT FOR OTHER INFLAMMATORY RHEUMATIC DISEASES?" Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 213–14. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2305.

Full text

Abstract:

BackgroundThe rheumatoid arthritis impact of disease score (RAID) is a patient-reported outcome measure to evaluate the impact of rheumatoid arthritis (RA) on patients’ quality of life (1). While an adapted instrument has been developed for psoriatic arthritis (2), there are no comparable instruments for other inflammatory rheumatic diseases. Since the RAID includes generic questions on pain, functional capacity, fatigue, physical and emotional well-being, sleep disturbances and coping, it could be an informative instrument beyond RA.ObjectivesTo analyse the performance of the RAID in ankylosi

APA, Harvard, Vancouver, ISO, and other styles

37

Pieczka, A., R. J. Evans, E. S. Grew, L. A. Groat, ,. C. Ma, and G. R. Rossman. "The dumortierite supergroup. II. Three new minerals from the Szklary pegmatite, SW Poland: Nioboholtite, (Nb0.6□0.4)Al6BSi3O18, titanoholtite, (Ti0.75□0.25)Al6BSi3O18, and szklaryite, □Al6BAs3+3O15." Mineralogical Magazine 77, no. 6 (2013): 2841–56. http://dx.doi.org/10.1180/minmag.2013.077.6.10.

Full text

Abstract:

AbstractThree new minerals in the dumortierite supergroup were discovered in the Szklary pegmatite, Lower Silesia, Poland. Nioboholtite, endmember (Nb0.6☐0.4)Al6B3Si3O18, and titanoholtite, endmember (Ti0.75☐0.25)Al6B3Si3O18, are new members of the holtite group, whereas szklaryite, endmember ☐Al6BAs3+3O15, is the first representative of a potential new group. Nioboholtite occurs mostly as overgrowths not exceeding 10 μm in thickness on cores of holtite. Titanoholtite forms patches up to 10 μm across in the holtite cores and streaks up to 5 μm wide along boundaries between holtite cores and th

APA, Harvard, Vancouver, ISO, and other styles

38

Botafogo, Vitor, Andrea Usas, Miriam Verdú-Bou, et al. "Profile of Inflammatory Biomarkers in Hodgkin Lymphoma. Differences between HIV-Negative and HIV-Positive Patients." Blood 144, Supplement 1 (2024): 6249. https://doi.org/10.1182/blood-2024-204572.

Full text

Abstract:

Introduction: People living with HIV have a 5-26 times higher risk of developing Hodgkin's lymphoma (HL) than the general population and its clinical presentation is usually more aggressive. Recent studies described an increase in inflammatory markers such as Interleukin-10 (IL-10), tumor necrosis factor α (TNFα) and IL-6 in both HIV-positive (HIVpos) and HIV-negative (HIVneg) patients with advanced HL compared to patients with localized disease. However, differences in the levels of inflammatory markers between HIVpos and HIVneg patients were not reported. Our aim was to compare the profile o

APA, Harvard, Vancouver, ISO, and other styles

39

Martín Moro, Fernando, Miguel Alcoceba, Samuel Romero, et al. "De Novo DLBCL with Concurrent Monoclonal B-Cell Lymphocytosis CLL-Type Exhibits Biological Characteristics Similar to Richter Syndrome." Blood 144, Supplement 1 (2024): 6267. https://doi.org/10.1182/blood-2024-211699.

Full text

Abstract:

Background: Richter Syndrome diffuse large B-cell lymphoma type (DLBCL-RS) is clinically and biologically different from de novo DLBCL, although the phenotypic profile comparison between both entities has scarcely been reported. Finding a minor monoclonal B-cell lymphoma (MBL) chronic lymphocytic leukemia (CLL) type population at de novo DLBCL diagnosis is not common and its biological and prognostic significance is unknown. Our aim is to characterize and compare DLBCL cases with prior or concomitant CLL (DLBCL-RS), de novo DLBCL with concurrent MBL CLL-type (DLBCL-MBL) and de novo DLBCL witho

APA, Harvard, Vancouver, ISO, and other styles

40

Deodhar, A., D. Van der Heijde, L. S. Gensler, et al. "POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 772–73. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2416.

Full text

Abstract:

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in a phase 2b study in patients (pts) with active ankylosing spondylitis.1,2ObjectivesTo assess efficacy and safety of BKZ vs placebo (PBO) in pts with active non-radiographic axial spondyloarthritis (nr-axSpA) up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 1.MethodsBE MOBILE 1 (NCT03928704) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were

APA, Harvard, Vancouver, ISO, and other styles

41

Francisco, Liton F., Saro Armenian, Mukta Arora, et al. "Progressive Decline in Late Mortality after Hematopoietic Cell Transplantation (HCT) over 40 Years - a Report from BMTSS." Blood 128, no. 22 (2016): 691. http://dx.doi.org/10.1182/blood.v128.22.691.691.

Full text

Abstract:

Abstract Background: The high intensity of therapeutic exposures (for autologous and allogeneic HCT) and chronic GvHD and its management (in allogeneic HCT) increase the risk for late mortality. Significant changes in transplantation strategies have been instituted over the past 4 decades, with the overarching goal of improving outcomes. The impact of these changes on late mortality remains unknown. Methods: We evaluated late mortality in 5,566 patients who had survived at least 2y after HCT performed between 1974 and 2010. Vital status information was ascertained as of May 2016, using medical

APA, Harvard, Vancouver, ISO, and other styles

42

Goldschmidt, Hartmut, Marc-A. Baertsch, Jana Schlenzka, et al. "Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse." Blood 132, Supplement 1 (2018): 253. http://dx.doi.org/10.1182/blood-2018-99-111203.

Full text

Abstract:

Abstract Introduction Salvage high dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is used in fit patients with relapsed multiple myeloma (RMM) in clinical practice. However, the role of this approach in the era of continuous novel agent based treatment has not been defined in randomized trials. The ReLApsE trial compared lenalidomide/dexamethasone (Rd) re-induction, salvage HDCT/ASCT and lenalidomide (R) maintenance with standard continuous Rd in a randomized controlled multicenter trial. Methods Between 2010 and 2016, 282 patients were randomized of whom 277

APA, Harvard, Vancouver, ISO, and other styles

43

Sweidan, Aroob, Sowjanya Vuyyala, Peter Xie, Mohammad Alhyari, Vrushali S. Dabak, and Zaher K. Otrock. "Hyperhemolysis Syndrome in SCD Patient: Reminder of a Rare but Life-Threatening Complication of Blood Transfusion." Blood 138, Supplement 1 (2021): 4282. http://dx.doi.org/10.1182/blood-2021-152788.

Full text

Abstract:

Abstract Background: Sickle cell disease (SCD) patients are at risk of developing multiple complications from transfusions, including alloimmunization to red blood cell (RBC) antigens, delayed hemolytic transfusion reactions, and hyperhemolysis syndrome (HS). HS is a serious complication of transfusion characterized by the destruction of both transfused and autologous RBCs with resulting severe anemia and post transfusion hemoglobin lower than pretransfusion levels. We report the case of a middle age female patient with known SCD who developed severe HS following a blood transfusion. We aim to

APA, Harvard, Vancouver, ISO, and other styles

44

Gladstone, Douglas Edward, Amanda Blackford, Yvette L. Kasamon, et al. "IGHV Mutational Status Is Prognostic in Del(11q) and Del(17p) Chronic Lymphocytic Leukemia." Blood 118, no. 21 (2011): 4598. http://dx.doi.org/10.1182/blood.v118.21.4598.4598.

Full text

Abstract:

Abstract Abstract 4598 Introduction The importance of interphase fluorescence in-situ hybridization (FISH) DNA analysis as a predictive tool for survival in patients with chronic lymphocytic leukemia (CLL) is well-established. However, even among cytogenetically defined groups, survival varies widely. In CLL patients who harbor del(13q), their IGHV mutational status predicts for Rai stage progression, treatment initiation and overall survival. Here we analyze, the influence of IGHV mutational status upon overall survival in CLL patients harboring the poor prognostic CLL FISH findings of a del(

APA, Harvard, Vancouver, ISO, and other styles

45

Hens, Luc, Nguyen An Thinh, Tran Hong Hanh, et al. "Sea-level rise and resilience in Vietnam and the Asia-Pacific: A synthesis." VIETNAM JOURNAL OF EARTH SCIENCES 40, no. 2 (2018): 127–53. http://dx.doi.org/10.15625/0866-7187/40/2/11107.

Full text

Abstract:

Climate change induced sea-level rise (SLR) is on its increase globally. Regionally the lowlands of China, Vietnam, Bangladesh, and islands of the Malaysian, Indonesian and Philippine archipelagos are among the world’s most threatened regions. Sea-level rise has major impacts on the ecosystems and society. It threatens coastal populations, economic activities, and fragile ecosystems as mangroves, coastal salt-marches and wetlands. This paper provides a summary of the current state of knowledge of sea level-rise and its effects on both human and natural ecosystems. The focus is on coastal urban

APA, Harvard, Vancouver, ISO, and other styles

46

Smolen, J. S., P. Emery, W. Rigby, et al. "POS0847 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 723–24. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2423.

Full text

Abstract:

BackgroundUpadacitinib (UPA), an oral JAK inhibitor, was shown to be safe and effective in improving the signs and symptoms of moderate-to-severe RA through 84 weeks (wks) when administered as monotherapy in patients (pts) with a prior inadequate response to MTX in the phase 3 SELECT-MONOTHERAPY trial (NCT02706951).[1]ObjectivesTo evaluate the efficacy and safety of UPA monotherapy up to wk 260 from the long-term extension (LTE) of SELECT-MONOTHERAPY.MethodsPts with active RA on stable MTX were randomly assigned to either continue MTX (cMTX) or switch to UPA monotherapy at 15 mg (UPA15) or 30

APA, Harvard, Vancouver, ISO, and other styles

47

Fitria Budi Utami. "The Implementation of Eating Healthy Program in Early Childhood." JPUD - Jurnal Pendidikan Usia Dini 14, no. 1 (2020): 125–40. http://dx.doi.org/10.21009/141.09.

Full text

Abstract:

   Eating habits develop during the first years of a child's life, children learn what, when, and how much to eat through direct experience with food and by observing the eating habits of others. The aim of this study is to get a clear picture of the Eating program Healthy, starting from the planning, implementation, supervision, and evaluation as a case study of nutrition education; to get information about the advantages, disadvantages and effects of implementing a healthy eating program for children. This research was conducted through a case study with qualitative data an

APA, Harvard, Vancouver, ISO, and other styles

48

Marian-Bălaşa, Marin. "The End of the Millennium in the Romanian Village. 2000. Ethnophonie CD 001. Recorded by Speranţa Rădulescu, Jacques Bouët, Bernart Lortat-Jacob, and Adriana Dan. Annotated by Speranţa Rădulescu. 8 pp. of notes in Romanian, English, and French. English translation by Margaret Beissinger, French translation by Jacques Bouët. 1 colour, 5 b/w photographs. 1 compact disc, 21 tracks (60:42). - Peasant Brass Bands from Moldavia: Zece Prăjini. 2000. Ethnophonie CD 002. Recorded by Speranţa and Valeriu Rădulescu. Annotated by Speranţa Rădulescu. 36 pp. of notes in English and French. English translation by Adrian Solomon and Dan Bora, French translation by Annie Bentoiu and Jacques Bouët. 3 colour, 4 b/w photographs. 1 compact disc, 18 tracks (58:11) - Outlaws of Yore (I). 2001. Ethnophonie CD 003. Recorded and annotated by Speranţa Rădulescu. 32 pp. of notes in English and French. English translation by Adrian Solomon, French translation by Annie Bentoiu and Jacques Bouët. 6 b/w photographs. 1 compact disc, 6 tracks (54:54). - Outlaws of Yore (II). 2001. Ethnophonie CD 004. Recorded and annotated by Speranţa Rădulescu. 36 pp. of notes in English and French. English translation by Adrian Solomon, French translation by Annie Bentoiu and Jacques Bouët. 8 b/w photographs. 1 compact disc, 8 tracks (57:34). - Romanian and Hungarian Music from Central Transylvania. 2001 Ethnophonie CD 005. Recorded by Speranţe Rădulescu, Costin Moisil, and Cristian Tarnoveţchi. Annotated by Speranţa Rădulescu. 24 pp. of notes in English and French. English translation by Adrian Solomon, French translation by Jacques Bouët. 3 colour, 5 b/w photographs. 1 compact disc, 17 tracks (63:54). - Romanian, Ukrainian, and Jewish Music from Maramureş. 2002. Ethnophonie CD 006. Recorded by Recorded by Speranţa and Valeriu Rădulescu, Costin Moisil, and Ioan Pop. Annotated by Speranţa Rădulescu. 32 pp. of notes in English and French. English translation by Adrian Solomon, French translation by Victor A. Stoichiţă. 3 colour, 7 b/w photographs. 1 compact disc, 15 tracks (60:46). - Gypsy Music from Transylvania. 2003. Ethnophonie CD 007. Recorded by Speranţa Rădulescu, Victor A. Stoichiţă, and Végh Oliver. Annotated by Speranţa Rădulescu and Emil Mihaiu. 24 pp. of notes in Romanian and English. English translation by Adrian Solomon. 3 colour, 6 b/w photographs. 1 compact disc, 21 tracks (64:22). - Roma and Gypsies from the Village of Gratia, Teleorman. 2004. Ethnophonie CD 008. Recorded by Speranţa and Valeriu Rădulescu. Annotated by Speranţa Rădulescu. 28 pp. of notes in Romanian and English. English translation by Adrian Solomon. 1 colour, 11 b/w photographs. 1 compact disc, 15 tracks (69:35). - Old Music from North Moldavia. 2004. Ethnophone CD 009. Recorded by Speranţa Rădulescu, Cristian Tarnoveţchi, and Florin Iordan. Annotated by Speranţa Rădulescu and Florin Iordan. 16 pp. of notes in Romanian and English. English translation by Adrian Solomon. 1 colour, 4 b/w photographs, 2 illustrations. 1 compact disc, 26 tracks (68:57)." Yearbook for Traditional Music 38 (2006): 163–66. http://dx.doi.org/10.1017/s0740155800011905.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Skeie, Bente Sandvei, Per Øyvind Enger, Jonathan Knisely, et al. "A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria." Neuro-Oncology Advances 2, no. 1 (2020). http://dx.doi.org/10.1093/noajnl/vdaa026.

Full text

Abstract:

Abstract Background A major challenge in the follow-up of patients treated with stereotactic radiosurgery (SRS) for brain metastases (BM) is to distinguish pseudoprogression (PP) from tumor recurrence (TR). The aim of the study was to develop a clinical risk assessment score. Methods Follow-up images of 87 of 97 consecutive patients treated with SRS for 348 BM were analyzed. Of these, 100 (28.7%) BM in 48 (53.9%) patients responded with either TR (n = 53, 15%) or PP (n = 47, 14%). Differences between the 2 groups were analyzed and used to develop a risk assessment score (the Bergen Criteria).

APA, Harvard, Vancouver, ISO, and other styles

50

Pohjonen, Jussi, Katri Kaukinen, Jukka Mustonen, and Satu Mäkelä. "MO243: Intestinal Fatty-Acid Binding Protein: A Potential Biomarker of Enterocyte Damage in IGA Nephropathy?" Nephrology Dialysis Transplantation 37, Supplement_3 (2022). http://dx.doi.org/10.1093/ndt/gfac067.042.

Full text

Abstract:

Abstract BACKGROUND AND AIMS An abundance of inflammatory cells has been found in duodena of IgA nephropathy (IgAN) patients [1, 2]. The degree of intestinal inflammation was shown to correlate with the amount of proteinuria and haematuria in IgAN [3]. Serum intestinal fatty-acid-binding protein (I-FABP) has shown to correlate with the degree of enterocyte damage in untreated coeliac disease (CD) patients [4]. The median level of I-FABP in untreated CD patients was 785 pg/mL and 173 pg/mL in healthy controls [5]. We conducted this study hypothesizing that I-FABP would be elevated in IgAN as a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!